ArticlePLoS genetics2022

An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency.

Kevin A Hope et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.